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Introduction: Ambulatory oxygen (O2) is prescribed to interstitial lung disease (ILD) patients
with mild hypoxemia, breathlessness and dyspnea on exertion. Oxygen titration is generally
done with the 6 minute walk test (6MWT) to determine the O2 flow preventing oxygen
saturation by pulse oximetry (SpO2) from falling below 88%. His study was designed to
generate a 6MWT index predicting the O2 flow allowing completion of the 6MWT without
oxygen desaturation.
Methods: Oxygen titration data from a group of 66 ILD patients and 30 controls, were used
to generate the algorithm determining an index (O2-GAP) predicting oxygen flow required to
complete a 6MWT without desaturation below 88%. This index was validated in a group of
93 ILD patients.
Results: The O2-GAP index, as obtained from the derivation population, (r
2 Z 0.97,
p < 0.001) was shown to correctly predict the oxygen flow required to complete the
6MWT without SpO2 falling below 88% validated in the validation population (r
2 Z 0.842;
p < 0.001).Diseases Unit, Department of Medicine, Policlinico Universitario “Tor Vergata”, Viale Oxford 81, 00133
torie@ptvonline.it, josuel78@gmail.com (J. Ora).
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6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 2015Conclusions: The O2-GAP index appears to be a useful tool to titrate ambulatory O2 with a
single 6MWT on room air in ILD patients with breathlessness and dyspnea on exertion.
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The use of long-term oxygen therapy (LTOT) effectively im-
proves disease symptoms and prolongs survival in chronic
obstructive pulmonary disease (COPD) patients with severe
hypoxemia (resting PaO2 on room air < 55 mmHg) [1e3].
However, oxygen is also administered to individuals with
moderate hypoxemia at rest for relief of breathlessness,
either as short-burst oxygen therapy or as ambulatory oxygen
therapy given during activities of daily living or exercise.
Although its efficacy in ameliorating both breathlessness and
exercise endurance is supported by a number of studies,
there are no data showing that it prolongs survival [4e7].
In patients with interstitial lung diseases (ILDs), a large
group of pulmonary disorders classified together because of
similar clinical, roentgenographic and physiologic features,
gas exchange worsening with exercise is recognized as a
central feature in disease pathophysiology [8,9]. The Royal
College of Physicians guidelines recommend LTOT in ILD pa-
tients with PaO2 below 60 mmHg and also advise to prescribe
oxygen to those patients who experience oxygen saturation
by pulse oximetry below 90% during a walk test on room air
[10]. Oxygen therapy has also been recently recommended
by the American Thoracic Society (ATS)/European Respira-
tory Society (ERS)/Japanese Respiratory Society (JRS)/Latin
America Thoracic Association (ALAT) idiopathic pulmonary
fibrosis (IPF) guidelines for diagnosis andmanagement, based
upon physiological reasons, extrapolation from data in COPD
and ethical concern over withholding oxygen therapy [9].
In this regard, ambulatory oxygen therapy has in fact
been shown to improve exercise capacity in the 6
minute walk test (6MWT) in IPF patients [11] and a recent
retrospective study on ILD patients including a majority of
patients with IPF, showed that ambulatory oxygen improves
patient performance in the 6MWT and ameliorates breath-
lessness [12].
A number of exercise tests have been used to evaluate
the efficacy of ambulatory and short-burst oxygen supple-
mentation, including the treadmill, cycle ergometry and the
6MWT, with a variety of oxygen supplementation devices
[13]. Overall, these studies have shown that the use of
ambulatory oxygen reduces exercise induced breathlessness,
may speed up recovery from breathlessness and improves
exercise capacity [7]. Generally, the amount of supple-
mental oxygen needed to compensate for exertional hypox-
emia is determined by repeating the 6MWT at different
oxygen flow rates in order to identify the lowest oxygen flow
rate needed to maintain oxygen saturation by pulse oximetry
above 88% [5,9,14,15]. Oxygen titration though, a time
consuming procedure, is taxing for the dyspneic patient. The
aim of this study was to develop and validate a 6MWT index,
obtained from a single test performed on room air, capable
of predicting the flow of ambulatory oxygen needed to
complete the test while maintaining oxygen saturation by
pulse oximetry (SpO2) equal or above 88%, without the need
of repeated testing using increasing oxygen flow rates.Material and methods
Design of the study
The study was designed to generate an algorithm to predict
the flow of supplemental oxygen [in liters per minute (l/
min) to be administered through a nasal cannula] required
to maintain oxygen saturation by pulse oximetry equal or
above 88% during the 6MWT in ILD patients, as monitored by
pulse oximetry. To this end, a group of 66 individuals with
ILD and from 30 subjects without cardiopulmonary disease,
were evaluated at the pulmonary function testing labora-
tory (PFT lab) of the Respiratory Diseases Unit of the Tor
Vergata University Hospital, Rome. The algorithm hitherto
derived was prospectively validated in a group of 93 ILD-
affected individuals.
The oxygen supplementation estimated by the algorithm
was defined as “O2-GAP index” so that when the 6MWT is
carried out on room air, the “O2-GAP index” indicated the
flow of supplemental oxygen required to maintain oxygen
saturation by pulse oximetry equal to or above 88%. When
the 6MWT was performed by patients already on supple-
mental oxygen, the “O2-GAP index” indicated the extra
flow of oxygen required to complete the test.
The study was approved by the Independent Ethics
Committee of the Tor Vergata University Hospital (Rome,
IT) and was conducted in accordance with the Declaration
of Helsinki (number: 156/12).Derivation population
A population of 96 subjects was evaluated between
October 1, 2008 and December 31, 2009. It was comprised
of 66 ILD-affected individuals, referred for dyspnea on
exertion, and 30 non ILD-affected subjects as the control
group, with pulmonary function tests within normal range
and no apparent clinico-radiological signs of cardiopul-
monary disease, who were referred for perceived breath-
lessness that resulted imputable to deconditioning,
metabolic causes (obesity) or anxiety. The ILD patient
group was comprised of 30 individuals with IPF, nine with
non specific interstitial pneumonia (NSIP), nine with
sarcoidosis, four with cryptogenic organizing pneumonia
(COP), three with hypersensitivity pneumonitis (HP), one
with berylliosis, two with undifferentiated connective
tissue disease, one with rheumatoid arthritis (RA), one
with histiocytosis-X (HX), one with lymphangio-
leiomyomatosis (LAM), one with neurofibromatosis, and
two with scleroderma. All subjects underwent pulmonary
function testing and the 6MWT. Individuals whose oxygen
saturation by pulse oximetry fell below 88% during the test
underwent oxygen titration, as described in the 6MWT
Section. The demographic, biological, pulmonary function
and echocardiographic characteristics of the derivation
population are shown in Table 1.
Table 1 Subjects’ characteristics of the derivation
population.
Control group
(n Z 30)
ILD
(n Z 66)
Male, n (%) 19 (63) 36 (55)
Age, yrs(a) 67  12 69  10
Height, cm(a) 165  11 162  9
Weight, kg(a) 80  17 76  13
Body mass index, kg/m2(a) 29  5 29  5
FEV1, %pr
(a) 100  15 81  23**
FVC, %pr(a) 98  22 81  24**
FEV1/FVC, %
(a) 79  7 77  19
TLC, %pr(a) 98  15 75  19**
RV, %pr(a) 101  28 75  22**
DLCO, %pr
(a) 79  16 48  22**
6MWT-distance, %pr(a) 89  28 72  27**
SpO2 at rest, %
(a) 97  2 95  2**
6MWT SpO2 nadir, %
(a) 95  2 85  6**
PAPs, mmHg(a,b) N/A 39  12
BMI: body mass index; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; TLC: total lung capacity; RV: resid-
ual volume; DLco: diffusing lung capacity for carbon monoxide;
6MWT: six minute walk test; SpO2: oxygen saturation by pulse
oximetry; PAPs: systolic pulmonary artery pressure; N/A: not
available.
a Mean  SD (T test, **p < 0.01).
b Data refer to 20 patients.
Table 2 Subjects’ characteristics of the validation
population.
ILD without
desaturations
(n Z 45)
ILD with
desaturations
(n Z 48)
Male, n (%) 27 (60) 21 (44)
Age, yrsa 66  13 68  11
Height, cma 161  9 164  9
Weight, kga 73  12 78  13
Body mass index, kg/m2a 28  5 29  4
FEV1, %pr
a 96  27 71  19**
FVC, %pra 98  25 68  17**
FEV1/FVC, %
a 78  9 83  11
TLC, %pra 87  16 67  15**
RV, %pra 85  22 71  28*
DLCO, %pr
a 62  18 35  14**
Distance, %pra 97  18 63  56**
SpO2 at rest, %
a 97  1 94  2**
6MWT SpO2 nadir, %
a 83  3 93  3**
PAPs, mmHga,b 36  10 37  7
BMI: body mass index; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; TLC: total lung capacity; RV: resid-
ual volume; DLco: diffusing lung capacity for carbon monoxide;
6MWT: six minute walk test; SpO2: oxygen saturation by pulse
oximetry, PAPs: systolic pulmonary artery pressure.
a Mean  SD (T test, **p < 0.01).
b Data refer to 32 patients, 11 ILD without desaturation and 21
ILD with desaturations.
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To validate the algorithm determining the O2-GAP index, a
population of 93 ILD-affected individuals undergoing exer-
cise testing with the 6MWT was prospectively evaluated.
They were 37 individuals with IPF, 20 with NSIP, 15 with
sarcoidosis, five with COP, four with HP, two with ber-
ylliosis, two with undifferentiated connective tissue dis-
ease, three with RA, two with scleroderma, one with
chronic eosinophilic pneumonia, one with HX, and one with
amiodarone induced fibrosis. The demographic, biological,
pulmonary function and echocardiographic characteristics
of the validation population are shown in Table 2.
All subjects performed the 6MWT on room air using a
portable device with pulse oximeter capability (Spirodoc,
MIR, Rome, Italy) carrying the O2-GAP determining algo-
rithm in its electronic memory (International Patent e PCT/
IT2010/000361) [16]. In those individuals whose oxygen
saturation by pulse oximetry would fell below 88% during
the test, the 6MWT was repeated to validate the O2-GAP
index obtained at the end of the test on room air, by
determining the flow of supplemental oxygen needed to
complete the test without oxygen desaturation.
Pulmonary function testing
Complete pulmonary function testing (PFT), including
forced vital capacity (FVC) and diffusing lung capacity
(DLCO), determined with the single breath technique, was
carried out according to the ATS guidelines [17] on a Master
Screen Body PFT (Jaeger, Wu¨rtzburg, Germany) usingEuropean Coal and Steel Community reference spirometric
values [18]. All subjects had PFTs within a week of the
6MWT. In addition, a subpopulation of study subjects un-
derwent echocardiographic estimate of systolic pulmonary
artery pressure.Six minute walk test
The 6MWTwas performed in a 30 m, straight indoor hallway
in accordance with the ATS guidelines [19]. All patients
included in the derivation and the validation populations
were tested under standardized conditions by trained op-
erators. Heart rate and oxygen saturation were measured
at rest (baseline), every minute during the test and at the
end of the test until recovery. A Nellcor N-20PATM Hand-
held Pulse Oximeter (Nellcor BS; Nellcor, Hayward, CA) was
used in the derivation population and a Spirodoc (MIR,
Rome, Italy) in the validation population. The algorithm
was loaded onto the latter pulse oximetry device (Spirodoc,
MIR, Rome, Italy, patent pending) for use with the valida-
tion population.
Supplemental oxygen was administered through a nasal
cannula, using commercially available integrated E-cylin-
der, valve and regulator device (Rivoira, Milan, Italy) car-
ried by the patient as per guideline recommendations [19].
Oxygen titration was carried out according to Leach RM
et al. [5], with sequential 6MWTs performed with two liter
increments from room air to six liters per minute (l/min),
until a SpO2 88% was obtained. Twenty minutes of rest
were allowed between tests. The lowest flow rate required
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appropriate oxygen supplementation. The distance walked
during the 6MWT (6MWT-distance) was expressed both as
absolute value in meters and as %predicted value (%pr),
using the Enright and Sherill equations [20].
O2-GAP index predicting algorithm
To generate the algorithm all the individual outcome var-
iables of the 211 6MWT (with and without oxygen supple-
mentation) performed by the subjects in the derivation
population were analyzed. Specifically the outcomes
analyzed included the SpO2 (mmHg) before and through
the test, the duration of the test (minutes), the recovery
time (seconds) necessary to reach the resting SpO2 after
the end of the 6MWT and the predicted distance (%),
compared to normality as indicated by the Enright and
Sherill equation [20].
Statistical analysis
Statistical analysis was carried out employing STATA 11
software (TX USA 2010), SPSS software and GraphPad Prism
software. Group comparisons were made using Student’s t-
test or one-way analysis of variance (ANOVA) as appro-
priate. A p value of less than 0.05 was considered statisti-
cally significant. Univariate correlations were examined
using Pearson’s product moment-correlation.
Results
Derivation of the algorithm determining the O2-GAP
index
The demographic, biological and pulmonary function char-
acteristics of the derivation population are shown in Table
1. ILD-affected individuals and control subjects were not
significantly different with regard to demographic and
biological characteristics.
In contrast, they had significantly different reduced
forced vital capacity (FVC), diffusing lung capacity for
carbon monoxide (DLCO) and distance walked in the 6MWT
(Table 1).
The O2-GAP index was determined by the following al-
gorithm (protected by the International Patent e PCT/
IT2010/000361) [16]:
Algorithm_coreZ
½ðAUCgap=MTÞþ ðBaseSpO2gap=7Þ2þ
ﬃﬃﬃﬃﬃﬃ
RT
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PPD
p þ ﬃﬃﬃﬃﬃﬃMTp
O2 GAP_indexZðalgorithm_coreÞ  8:35
4:56
AUCgap is the difference between the area under the
curve delimited by the function f(X ) Z 100 and the area
under the curve of SpO2 of the patient during the test. The
area is delimited by T0 and T6 (expressed in minutes); when
the test was interrupted earlier than 6 min, T would be
equal to Tminutes walked. MT (minutes of test) is the time
of the test (expressed in minutes). BaseSpO2gap is thedifference between 100 and the SpO2 at rest. RT (recovery
time) is the recovery time (in seconds) needed for SpO2 to
return to its initial value. PPD (percent predicted distance)
is the MWTdistance expressed in percent according to the
Enright and Sherill equation [20].
A number of variables was significantly different be-
tween individuals requiring no oxygen and those requiring
supplemental oxygen to complete the 6MWT, but as shown
in Table 3 none of them though was able to discriminate
among tests clustered according to the magnitude of oxy-
gen flow needed, as determined by oxygen titration.
By computational analysis of the 6MWT variables recor-
ded from the subjects included in the derivation population
we obtained a composite dependent variable f(x) called
“algorithm core”. The control group, including subjects
without pulmonary disease and without spirometric ab-
normalities, was analyzed in order to identify a “zero-
point” for the algorithm model. As showed in Fig. 1, the
algorithm core is significantly correlated with the oxygen
supplementation (r2 Z 0.97, p 0.001) and allows to
discriminate tests clustered according to oxygen flow
needed to complete the walk test. The geometric solution
of the equation “algorithm core Z 4.56X þ 8.35” predicts
the magnitude of supplemental oxygen flow required by
each subject to complete the 6MWT without oxygen desa-
turation. This figure is hereafter defined as O2-GAP index.
By applying the equation to the 6MWT performed by the
same subjects with the amount of supplemental oxygen
corresponding to that predicted by the O2-GAP index
determined on the first test on room air, we were able to
show that the O2-GAP index re-calculated on ambulatory
oxygen was zeroed out, or significantly reduced in com-
parison with the first O2-GAP index (p < 0.05; Fig. 2).Validation of the algorithm determining the O2-GAP
index
Of the 93 ILD-affected subjects included in the validation
population, 45 completed the 6MWT on room air while
maintaining oxygen saturation by pulse oximetry equal to or
above 88%, while 48 desaturated during the test and
required oxygen supplementation to complete the 6MWT
(Table 2, Fig. 3). Demographic and biological characteris-
tics of the individuals who did desaturate during the test
were not different from those who did not. Physiological
parameters, FVC, DLCO and the 6MWT-distance were
significantly worse in those who did desaturate while sys-
tolic pulmonary artery pressure at echocardiography was
not (Table 2).
There was a statistically significant correlation between
the observed magnitude of the supplemental flow of oxy-
gen required for patients desaturating on room air to
complete the 6MWT while maintaining oxygen saturation
by pulse oximetry equal to or above 88% and the pre-
dicted O2-GAP index value (r Z 0.918; r
2 Z 0.842;
p < 0.001) (Fig. 4). On average, the supplemental flow of
oxygen predicted by the O2-GAP index was in excess of the
flow determined by oxygen titration in the same subjects
by 0.7 l/min. On the other hand, the O2-GAP index was
below the flow of oxygen determined by titration in only
three subjects (Fig. 4).
Table 3 ANOVA analysis of variables of 6MWT performed by patients of the study population (n Z 96) by oxygen supple-
mentation clusters.
One-way ANOVA and Bonferroni’s post test P values
SpO2
at rest
SpO2
nadir
Meters
(%)
Recovery
time (min)
Duration
of test (min)
Algorithm
core
0 l/min vs 2 l/min *** *** ns ns ns ***
0 l/min vs 4 l/min *** *** *** ns *** ***
0 l/min vs 6 l/min *** *** *** ns * ***
2 l/min vs 4 l/min ns ns ns ns *** ***
2 l/min vs 6 l/min ns ns * ns * ***
4 l/min vs 6 l/min ns ns ns ns ns *
*p < 0.05, **p < 0.01, ***p < 0.001, ns: p > 0.05.
2018 J. Ora et al.Consistent with the improvement of oxygen saturation,
the supplemental flow of oxygen was also adequate to
improve exercise capacity in patients desaturating on room
air. Their average 6MWT-distance rose from 226  161 m on
room air to 405 96 m on supplemental oxygen (p< 0.0001).
In addition, the amount of supplemental flow of oxygen also
improved upon these patients breathlessness at rest (Borg
score on room air, 1  1.7, on ambulatory oxygen 0.6  1.2,
p < 0.05), but not on dyspnea on exercise.
Discussion
Typically, the ILD-affected patients present with impaired
gas exchange. This may be caused by multiple abnormal-
ities, including ventilation/perfusion mismatch, O2 diffu-
sion limitation, low mixed venous pO2, right-to-left intra-
cardiac shunt or pulmonary hypertension [21]. In these
patients, gas exchange deteriorates during exercise leading
to markedly decreased oxygen saturation by pulse oximetry
and O2 arterial blood pressure [22]. Although both long-
term and ambulatory oxygen therapy have been recom-
mended for IPF patients with mild hypoxemia [9], there is
no firm agreement on how to gauge the need for oxygen
supplementation. The cardiopulmonary exercise testFigure 1 O2-GAP algorithm core distribution by Whiskers box
(10e90 percentile) of n Z 211 6MWTs performed by the study
population; f(X ) represents the dependent variable of the al-
gorithm that predicts the O2-GAP index.(CPET) is not as sensitive as the 6MWT for detecting oxygen
desaturation in patients with respiratory disease [23,24]. In
addition, the 6MWT is a simple and efficient low cost tool
with which to evaluate the performance of individuals
during sub-maximal exercise. It can be safely applied to
patients with heart and/or advanced lung disease and it has
been shown to be highly reproducible in patients with
pulmonary fibrosis [25]. Although the 6MWT is the most
commonly used test to prescribe oxygen therapy, most
guidelines do not give clear indications on how to dose
supplemental oxygen for ambulatory oxygen therapy.
Consequently, recommendations for oxygen prescription
vary in different countries [26].
This study has some limitations. Firstly, patients were
not familiarized with the 6MWT and the possibility that
oxygen titration itself improved the patient performance
due to a learning effect cannot be ruled out. On the other
hand, the increased work of carrying the oxygen cylinder in
the repeat tests could have a negative effect on the test.
Secondly, the study population included ILD patients with
different interstitial diseases. Although all patients had
reduced lung volumes without marked flow obstruction,
patients with different interstitial disorders may have
varying degrees of parenchymal and vascular derangement
differently affecting gas exchange. Thirdly, the formula
was computed on data obtained using a continuous oxygen
flow nasal cannula (CFNC) device, and the results cannot be
extended as such to pulse dose devices.
Even with these limitations, this study shows that the O2-
GAP composite index can predict the flow (l/min) of sup-
plemental ambulatory oxygen required to complete a 6MWT
without desaturation, while the individual variables of the
algorithm core, such as the 6MWT-distance, the 6MWT SpO2
nadir and the distance walked, when used independently do
not correlate with the dose of ambulatory oxygen to be
supplemented. It also shows that the O2-GAP index allows to
“titrate” ambulatory oxygen dose with a single 6MWT. Te
algorithm core of the O2-GAP index was designed with the
primary goal of identifying a dose of oxygen sufficient to
prevent dyspnea, oxygen desaturation and breathlessness on
exercise. Hence, the O2-GAP index slightly overestimated the
oxygen flow required to maintain oxygen saturation by pulse
oximetry during the 6MWT in the majority of patients while
underestimating it in three patients only. As ILD patients,
and the IPF affected in particular, tend not to develop
Figure 2 Regression of the O2-GAP index by increasing the oxygen supplementation. Data are expressed as Whiskers box (10e90
percentile, mean and median) 6MWTs performed by n Z 96 patients of the study population.
6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 2019hypercarbia until terminally ill, the data strongly suggest
that the O2-GAP index could be safely and reliably used in
clinical management of these patients.
Oxygen titration is both time consuming and expensive
and may not be carried out routinely in the follow up of ILD
patients. A survey carried out by Wijkstra et al. in 2001
showed that oxygen at rest, during sleep and during exer-
cise was variably prescribed by pulmonologists [26] without
standardized titration, as recommended by the Royal Col-
lege of Physicians in the UK. In this context, a standardized
measure, such as the O2-GAP, might be of considerable help
with simplifying oxygen prescription and might provide a
reference against which to compare individual protocols
[11,15,26]. Not only it does allow to reliably determine
ambulatory oxygen dose within a single 6MWT, but it also
allows re-assessing oxygen dosage in patients already on
supplemental oxygen as the algorithm recalculates the O2-
GAP with a 6MWT on supplemental oxygen to determine the
“extra” oxygen required. In this regard, it is worth noticing
that, different from 6MWT parameters such as oxygen
saturation or distance walked, the O2-GAP index is not
affected by the oxygen supplementation, as it may measure
oxygen requirement in addition to the O2 flow already
administered, thus allowing the comparison of 6MWTs
performed over time, at different oxygen flow rates.
A number of studies has compared CFNC and DOD de-
vices for oxygen supplementation, suggesting that they
perform similarly, at lead for oxygen supplementation
[27,28]. Our study evaluated the validity of the O2-GAP
index using continuous oxygen flow by standard nasal can-
nula. Further studies are needed to assess the applicabilityand clinical utility of the measure of the O2-GAP index to
using currently available oxygen conserving devices.
To the best of our knowledge, the O2-GAP index is the
first index capable of estimating the dose of oxygen sup-
plementation in patients with ILD, upon the performance of
a single 6MWT. In the context of the lack of standardization
of oxygen prescription to dyspneic ILD patients, the avail-
ability of an algorithm that can be uploaded on the elec-
tronic memory of portable pulse oximetry devices, might
considerably simplify oxygen titration and facilitate the use
of the 6MWT for oxygen prescription.
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